EUCTR2008-006840-20-IT进行中（未招募）不适用
Planned Transition to Sirolimus-based Therapy Versus Continued Tacrolimus-based Therapy in Renal Allograft Recipients - ND
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female subjects aged 18 years or older.
- •2.Will receive or have received, no earlier than 14 days prior to transplantation and no later than 2 days after transplantation, a primary, living- or deceased-donor renal allograft.
- •3.All female and male subjects who are biologically capable of having children must agree and commit to the use of a reliable method of birth control for the duration of the study and for 3 months after the last dose of test article. A subject is biologically capable of having children even if he or she is using contraceptives or if his or her sexual partner is sterile or using contraceptives.
- •RANDOMIZATION
- •1.Ninety (90) to 150 days post-transplantation.
- •2.Treatment with TAC and an IMPDH inhibitor initiated ≤ 30 days of transplantation and has remained on both for the 30 days prior to randomization.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Recipients of multiple organ transplants (i.e., prior or concurrent transplantation of any organs other than renal transplant).
- •2.Recipients of adult or pediatric en bloc kidney transplants.
- •3.Recipients who required or will require desensitization protocols.
- •4.Known history of focal segmental glomerulosclerosis (FSGS) or membranoproliferative glomerulonephritis (MPGN).
- •5.Evidence of active systemic or localized major infection, as determined by the investigator.
- •6.Received any investigational drugs or devices ≤ 30 days prior to transplantation.
- •7.Known or suspected allergy to SRL, TAC, IMPDH inhibitor, macrolide antibiotics, or other compounds related to these classes of medication.
- •8.Planned treatment with immunosuppressive therapies other than those described in the protocol.
- •9.History of malignancy ≤ 3 years of screening (except for adequately treated basal cell or squamous cell carcinoma of the skin).
- •10.Recipients who are known to be human immunodeficiency virus (HIV) positive.
- •11.Women who are biologically capable of having children with a positive urine or serum pregnancy test.
- •12.Breastfeeding women.
- •RANDOMIZATION
- •1.Any major illness/condition that, in the investigators judgment, will substantially increase the risk associated with the subjects participation in and completion of the study, or could preclude the evaluation of the subjects response.
- •2.Treatment with immunosuppressive therapies other than those described in the protocol.
- •3.Subjects who underwent CS withdrawal or avoidance and did not receive antibody induction at the time of transplantation with anti-thymocyte globulin (rabbit) (rATG) (Thymoglobulin) or alemtuzumab (Campath).
- •4.Subjects who have had CS discontinued ≤ 30 days before randomization.
- •5.Calculated GFR < 40 mL/min/1.73m2 using the simplified Modification of Diet in Renal Disease (MDRD) formula ≤ 2 weeks prior to randomization.
- •6.Spot urine protein to creatinine ratio (UPr/Cr) ≥ 0.5 ≤ 2 weeks prior to randomization.
- •7.Banff (2007) grade 2 or higher acute T-cell-mediated or any acute antibody-mediated rejection at any time post-transplantation.
- •8.Any acute rejection (biopsy-confirmed or presumed) ≤ 30 days before randomization.
- •9.More than 1 episode of acute rejection (biopsy-confirmed or presumed).
- •10.Known Banff (2007) interstitial fibrosis and tubular atrophy (IF/TA) ≥ grade 2 or recurrent/de novo glomerular disease.
- •11.Major surgery ≤ 2 weeks prior to randomization.
- •12.Active post-operative complication, e.g. infection, delayed wound healing.
- •13.Total white blood cell count < 2,000/mm3 or absolute neutrophil count (ANC) < 1000, platelet count < 100,000/mm3 ≤ 2 weeks prior to randomization.
- •14.Fasting triglycerides > 400 mg/dL (> 4.5 mmol/L) or fasting total cholesterol > 300 mg/dL
- •(> 7.8 mmol/L) ≤ 2 weeks prior to randomization despite lipid-lowering therapy.
- •15.Women who are biologically capable of having children with a positive urine or serum pregnancy test.
- •16.Breastfeeding women.
研究者
相似试验
进行中（未招募）
不适用
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant RecipientsRenal function in kidney transplantMedDRA version: 14.0Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2008-006840-20-DEWyeth, a Pfizer Company256
进行中（未招募）
1 期
Planned Transition to Sirolimus-based Therapy Versus Continued Tacrolimus-basedTherapy in Renal Allograft Recipients.Transición programada a un tratamiento basado en sirolimus frente a la continuación de un tratamiento basado en tacrolimus en receptores de un alotrasplante renalRenal function in kidney transplantFunción renal en trasplantados renalesMedDRA version: 9.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionEUCTR2008-006840-20-ESWyeth Pharmaceuticals Inc254
已完成
4 期
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant RecipientsGraft RejectionKidney TransplantRenal Allograft RecipientsRenal TransplantNCT00895583Pfizer254
尚未招募
不适用
Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting Stent Trial: Extended Follow-up StudyCoronary Artery DiseaseJPRN-UMIN000030732Research Institute for Production Development3,196
撤回
不适用
Switching From One Type of Anti-rejection Drug (Tacrolimus or Cyclosporine) to Another (Sirolimus) Approximately 90-180 Days After Liver TransplantationSide Effects of Calcineurin InhibitorsRenal ToxicityHepatic Fibrosis on BiopsyNeurotoxicityPost Transplant DiabetesNCT00834496Thomas Jefferson University